UCSF researchers map 1,881 protein interactions to unlock new autism therapies

Researchers at UC San Francisco's Quantitative Biosciences Institute (QBI) and the Department of Psychiatry and Behavioral Sciences have developed the largest molecular interaction map of autism to date. The study, published in the journal Science, provides a critical link between genetic risk factors and the actual biological machinery of the brain.

By mapping 100 high-confidence autism risk genes, the team identified 1,881 protein-protein interactions. According to the study, 87% of these interactions were previously unknown to science. A key finding is that while autism is genetically diverse, these various mutations often converge on a small number of shared protein complexes, or "molecular hubs," including one involving the protein DCAF7. The research also clarified a specific mechanism involving FOXP1; a mutation in this gene prevents it from binding to FOXP4, which causes the "cut free" FOXP4 to bind to incorrect genomic regions, triggering hyperactive electrical firing and premature neuron growth.

The challenge of genetic diversity

For decades, scientists have identified hundreds of individual risk genes associated with autism spectrum disorder. However, the sheer volume of these mutations made it difficult to understand how they collectively altered brain development. Because different patients often have different mutations, creating a "one-size-fits-all" drug has remained elusive. This new map allows researchers to see past the individual mutations to the shared biological pathways they disrupt.

A shift toward molecular hubs

This discovery shifts the therapeutic focus from targeting hundreds of individual mutations to targeting a few shared molecular hubs. By focusing on these convergence points, scientists believe they can develop scalable and tolerable drugs for profound autism, which affects approximately 30% of diagnoses.

Nevan J. Krogan, PhD, director of QBI, stated that the study maps the exact molecular machinery that is altered and serves as a blueprint for translating the genetics of almost any disease—including cancer and neurodegeneration—into a real therapeutic strategy. Matthew W. State, MD, PhD, chair of the UCSF Department of Psychiatry and Behavioral Sciences, added that the work opens a "whole new world of possibilities" for therapeutic targets and promises a generation of novel drugs to transform clinical care.

Future implications

While the map provides a massive leap in understanding, the next phase involves testing whether targeting these hubs can actually reverse or mitigate symptoms in clinical settings. The generalizable nature of this protein-protein interaction approach suggests that similar maps could be created for other complex genetic disorders, potentially accelerating the timeline for precision medicine across neurology and oncology.